Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells

References

• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer2015136E359E38625220842
   PubMed Web of Science ®Google Scholar
• FisherRGoreMLarkinJCurrent and future systemic treatments for renal cell carcinomaSemin Cancer Biol201323384522705280
   PubMed Web of Science ®Google Scholar
• BedkeJGaulerTGrunwaldVSystemic therapy in metastatic renal cell carcinomaWorld J Urol20173517918827277600
   PubMed Web of Science ®Google Scholar
• HurvitzSAKalousOConklinDIn vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of responseBreast Cancer Res Treat201514966968025663547
   PubMed Web of Science ®Google Scholar
• LeeSJLeeJLeeJPhase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patientsInvest New Drugs2013311580158624013904
   PubMed Web of Science ®Google Scholar
• WedelSHudakLSeibelJMInhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001Life Sci20118841842421192952
   PubMed Web of Science ®Google Scholar
• KaramJAZhangXYTamboliPDevelopment and characterization of clinically relevant tumor models from patients with renal cell carcinomaEur Urol20115961962821167632
   PubMed Web of Science ®Google Scholar
• FrançoisRAMaengKNawabATargeting focal adhesion kinase and resistance to mTOR inhibition in pancreatic neuroendocrine tumorsJ Natl Cancer Inst2015107djv12325971297
   PubMedGoogle Scholar
• HuangJJLiZMHuangYSchedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugsInvest New Drugs20123022323520960030
   PubMed Web of Science ®Google Scholar
• CalderwoodSKTumor heterogeneity, clonal evolution, and therapy resistance: an opportunity for multitargeting therapyDiscov Med20131518819423545047
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTEGlenHLenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trialLancet Oncol2015161473148226482279
   PubMed Web of Science ®Google Scholar
• ColwellJFDA approves drug combo for kidney cancerCancer Discov20166687688
   Web of Science ®Google Scholar
• GrimaldiASantiniDZappavignaSAntagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cellsCancer Biol Ther20151656757925866016
   PubMed Web of Science ®Google Scholar
• ButlerDEMarleinCWalkerHFInhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancerOncotarget20178566985671328915623
   PubMedGoogle Scholar
• SheppardKECullinaneCHannanKMSynergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitorsEur J Cancer2013493936394424011934
   PubMed Web of Science ®Google Scholar
• RobertsPJUsaryJEDarrDBCombined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer modelsClin Cancer Res2012185290530322872574
   PubMed Web of Science ®Google Scholar
• SatonakaHIshidaKTakaiM(−)-Epigallocatechin-3-gallate down-regulates doxorubicin-induced overexpression of P-glycoprotein through the coordinate inhibition of PI3K/Akt and MEK/ERK signaling pathwaysAnticancer Res2017376071607729061787
   PubMed Web of Science ®Google Scholar
• OlowAMuellerSYangXBRAF status in personalizing treatment approaches for pediatric gliomasClin Cancer Res2016225312532127217440
   PubMed Web of Science ®Google Scholar
• KiesslingMKCurioni-FontecedroASamarasPTargeting the mTOR complex by everolimus in NRAS mutant neuroblastomaPLoS One201611e014768226821351
   PubMed Web of Science ®Google Scholar
• NishiokaCIkezoeTYangJYokoyamaAInhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1Apoptosis20101579580420221697
   PubMed Web of Science ®Google Scholar
• SahniSMerlotAMKrishanSGene of the month: BECN1J Clin Pathol20146765666024811486
   PubMed Web of Science ®Google Scholar
• LuiANewJOgonyJEverolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cellsBMC Cancer20161648727421652
   PubMed Web of Science ®Google Scholar
• ZhangXYangHYueSThe mTOR inhibition in concurrence with ERK1/2 activation is involved in excessive autophagy induced by glycyrrhizin in hepatocellular carcinomaCancer Med201761941195128675698
   PubMed Web of Science ®Google Scholar
• AltmeyerAJossetEDenisJMThe mTOR inhibitor RAD001 augments radiation induced growth inhibition in a hepatocellular carcinoma cell line by increasing autophagyInt J Oncol2012411381138622895785
   PubMed Web of Science ®Google Scholar
• ZouYWangJLengXThe selective ERK inhibitor selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivoOncotarget20178208252083328212559
   PubMedGoogle Scholar
• WangAZhangHLiangZAntagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cellsCancer Biol Ther20151656757925866016
   PubMed Web of Science ®Google Scholar
• YangYHuLZhengHApplication and interpretation of current autophagy inhibitors and activatorsActa Pharmacol Sin20133462563523524572
   PubMed Web of Science ®Google Scholar
• ShiTTYuXXYanLJResearch progress of hydroxychloroquine and autophagy inhibitors on cancerCancer Chemother Pharmacol20177928729427889812
   PubMed Web of Science ®Google Scholar
• RosenfeldMRYeXSupkoJGA phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiformeAutophagy2014101359136824991840
   PubMed Web of Science ®Google Scholar
• JiangMLiuKLuoJDongZAutophagy is a renoprotective mechanism during in vitro hypoxia and in vivo ischemia-reperfusion injuryAm J Pathol20101761181119220075199
   PubMed Web of Science ®Google Scholar
• LiuTWuLWangDRole of reactive oxygen species-mediated MAPK and NF-κB activation in polygonatum cyrtonema lectin-induced apoptosis and autophagy in human lung adenocarcinoma A549 cellsJ Biochem201616031532427318358
   PubMed Web of Science ®Google Scholar
• HungACTsaiCHHouMFThe synthetic β-nitrostyrene derivative CYT-Rx20 induces breast cancer cell death and autophagy via ROS-mediated MEK/ERK pathwayCancer Lett201637125126126683774
   PubMed Web of Science ®Google Scholar
• HuangXLZhangHYangXYActivation of a C-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cellsAnticancer Drugs20172859660228430744
   PubMed Web of Science ®Google Scholar
• DaiJPZhaoXFZengJDrug screening for autophagy inhibitors based on the dissociation of Beclin1-Bcl2 complex using BiFC technique and mechanism of eugenol on anti-influenza A virus activityPLoS One20138e6102623613775
   PubMed Web of Science ®Google Scholar
• HeWWangQSrinivasanBA JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapyOncogene2014333004301323831571
   PubMed Web of Science ®Google Scholar
• YuenJSSimMYSimHGCombination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinomaInt J Oncol20124171272022641227
   PubMed Web of Science ®Google Scholar